Previous studies also showed that intestinal microbiota and its products have cross reactivity with tumor neoantigens, which could enhance antigen presentation and stimulate T‐cell activation,104, 105 while the use of TAB could disrupt intestinal microbiota and was associated with worsened prognosis in patients with aRCC receiving PD‐1/PD‐L1 mAbs.106. The gene discussed is PDCD1; the disease is neoplasm.